HR+ breast cancer The PALOMA-3 trial announced in April 2015 that the addition of<unk>  was superior to fulvestrant alone for progression-free survival. In the phase II PALOMA-1 trial reported at the April 2014 annual meeting of the American Association for Cancer Research, the addition of<unk>  to letrozole was shown to significantly slow the progression of advanced cancer (median progression-free survival increased from 10.2 months to 20.2 months), but was not shown to have a statistically significant effect on increasing patients' overall survival times. Pfizer announce on May 31, 2020 the results of a preplanned efficacy and futility analysis. The results indicate that, when used in combination with post-surgery endocrine therapy, it "is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS)." The trial was conducted on male and female patients with HR-positive, HER2-negative early stage breast cancer. Active clinical trials According to the NIH National Cancer Institute there are currently 39 active clinical trials testing<unk>  on its own or in combination with other medications. While a majority of these are exploring the further uses of<unk>  to treat breast cancer, other trials are investigating the potential applications of<unk>  to head and neck cancers, non-small cell lung cancer, recurring brain metastasis, squamous cell carcinoma, central nervous system tumors, and other solid tumor types. In December 2017, Pfizer announced that the PALOMA-2 trial, an ongoing phase III trial combining<unk>  with letrozole, showed a 44% reduction in risk of disease progression among trial subjects. The trial has also demonstrated greater than a year's improved median progression free survival for patients on the combined therapy (as compared to letrozole on its own). PALOMA-2 median patient follow-up time now exceeds three years, making it the longest traceable data for phase III study of a CDK4/6 inhibitor.<unk>  is currently in Phase 2 clinical trials as a combination treatment with oral SERD’s for ER+/HER2- breast cancer. Studies include<unk>  plus G1 Therapeutic’s rintodestrant and Zentalis’s Zn-c5.
Palbociclib
Ribociclib
Tamoxifen
Enzalutamide
Trastuzumab
Lasofoxifene
Bazedoxifene
Anastrozole